MedTrace Logo

L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function

NCT00213915 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-22

No results posted yet for this study

Summary

* exercise capacities are still altered after heart transplantation partly due to peripheral endothelial dysfunction
* cyclosporin-induced renal dysfunction may be due to renal endothelial dysfunction and can be reversed in an animal model by L-arginine supplementation
* to determine the potential beneficial effect of L-arginine supplementation on exercise capacity and renal function of heart transplant recipients

Conditions

  • Heart Transplantation

Interventions

DRUG

12 g of L-arginine glutamate during 6 weeks twice a day

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Stephane DOUTRELEAU, MD · Service de Physiologie et d'Explorations Fonctionnelles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Completion
2004-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00213915 on ClinicalTrials.gov